A new era in point-of-care diagnostic

Meritas® stands for strength, merit and truth.

The acquisition of Fiomi Diagnostics by Trinity Biotech in early 2012 brought together experts in the field of diagnostics, forming an entrepreneurial team that embarked on a mission to create a suite of products to herald a new era in cardiac diagnostics; Meritas®.

Trinity Biotech, founded in 1992, is a world leader in the development, manufacture and marketing of diagnostic test kits, while Fiomi Diagnostics has been dedicated to the development of accurate, precise cardiac biomarker tests since its inception. The acquisition was the beginning of a new dawn in reliable, accurate point-of-care (POC) testing, using our combined talents to give medical professionals worldwide the opportunity to benefit from POC testing with the groundbreaking Meritas®.

Historically, there has been a lack of reliable testing at the point of patient care. Acute care clinicians worldwide recognize the urgent need for laboratory standard POC testing to ensure the quality, reliability and accuracy of results.

The revolutionary Meritas® POC Analyzer, with its current and future menu of tests, sets a new standard for point-of-care testing, including the only guideline-compliant POC Troponin assay – the Meritas® Troponin I test. This allows fast, cost-effective and accurate triage, enabling rapid intervention for improved patient outcomes.

Meritas® – your best decision at the point of care